ArticlemAbs2015
Recombinant renewable polyclonal antibodies.
Article in mAbs, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Discovering Novel Therapeutic VbioRxiv : the preprint server for biology · 2026Article
- Discovering novel therapeutic VFrontiers in immunology · 2026Article
- Article
- Sequencing of Polyclonal Antibodies by Integrating Intact Mass, Middle-Down, and De Novo Bottom-Up Mass Spectrometry.Molecular & cellular proteomics : MCP · 2025Article
- Fit-for-purpose heterodivalent single-domain antibody for gastrointestinal targeting of toxin B from Clostridium difficile.Protein science : a publication of the Protein Society · 2024Article
- Characterization of two affinity matured Anti-Yersinia pestis F1 human antibodies with medical countermeasure potential.PloS one · 2024Article
- Direct selection of functional fluorescent-protein antibody fusions by yeast display.PloS one · 2023Article
- A pandemic-enabled comparison of discovery platforms demonstrates a naïve antibody library can match the best immune-sourced antibodies.Nature communications · 2022Article
- Validation of antibodies: Lessons learned from the Common Fund Protein Capture Reagents Program.Science advances · 2021Article
- A single donor is sufficient to produce a highly functional in vitro antibody library.Communications biology · 2021Article
- A general strategy to control antibody specificity against targets showing molecular and biological similarity: Salmonella case study.Scientific reports · 2020Article
- Advances in the Production and Batch Reformatting of Phage Antibody Libraries.Molecular biotechnology · 2019Review
- Article
- Recombinant Antibodies against Mycolactone.Toxins · 2019Article
- Antibodies Used to Detect Glaucoma-Associated Myocilin: More or Less Than Meets the Eye?Investigative ophthalmology & visual science · 2019Review
- Epitope mapping of commercial antibodies that detect myocilin.Experimental eye research · 2018Article
- Selection of phage-displayed accessible recombinant targeted antibodies (SPARTA): methodology and applications.JCI insight · 2018Article
- Highly multiplexed and quantitative cell-surface protein profiling using genetically barcoded antibodies.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Many Routes to an Antibody Heavy-Chain CDR3: Necessary, Yet Insufficient, for Specific Binding.Frontiers in immunology · 2018Article
- Ligand-targeted theranostic nanomedicines against cancer.Journal of controlled release : official journal of the Controlled Release Society · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Only a small fraction of the antibodies in a traditional polyclonal antibody mixture recognize the target of interest, frequently resulting in undesirable polyreactivity. Here, we show that high-quality recombinant polyclonals, in which hundreds of different antibodies are all directed toward a target of interest, can be easily generated in vitro by combining phage and yeast display. We show that, unlike traditional polyclonals, which are limited resources, recombinant polyclonal antibodies can be amplified over one hundred million-fold without losing representation or functionality. Our protocol was tested on 9 different targets to demonstrate how the strategy allows the selective amplification of antibodies directed toward desirable target specific epitopes, such as those found in one protein but not a closely related one, and the elimination of antibodies recognizing common epitopes, without significant loss of diversity. These recombinant renewable polyclonal antibodies are usable in different assays, and can be generated in high throughput. This approach could potentially be used to develop highly specific recombinant renewable antibodies against all human gene products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.